MedTrace Logo

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

NCT02880293 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2024-12-06

Study results available
· View outcomes & findings →

Summary

This study will test whether half matched donors with favorable KIR genes will reduce the risk of cancer recurring after transplant.

Conditions

  • Hematologic Malignancy

Interventions

DRUG

melphalan

melphalan (140 mg/m2 IV on day -7)

DRUG

fludarabine

fludarabine (40 mg/m2/d on days -5 through -2)

DRUG

thiotepa

thiotepa (5 mg/kg IV on day -67)

DRUG

Cyclophosphamide

cyclophosphamide (50 mg/kg IV on day +3 and +4)

DRUG

Mesna

DRUG

Mycophenolate Mofetil

(15 mg/kg PO/IV TID)

DRUG

Filgrastim

DRUG

Tacrolimus

Sponsors & Collaborators

Principal Investigators

  • Brian Shaffer, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-23
Primary Completion
2023-11-20
Completion
2023-11-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02880293 on ClinicalTrials.gov